Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BEARISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Merck & Co., Inc. (MRK) AI Forecast

Our AI ranks Merck & Co., Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$MRK Bearish Signal Full forecast available

Merck & Co., Inc. (MRK) Stock Forecast Sept. 24, 2026


Merck & Co., Inc. (MRK) AI Stock Price Forecast & Investment Analysis

Merck & Co., Inc. Stock Price Chart and Technical Analysis

Loading chart...

Merck & Co., Inc. (MRK) - Comprehensive Stock Analysis & Investment Research

Deep dive into Merck & Co., Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Merck & Co., Inc. Investment Summary

When evaluating whether Merck & Co., Inc. (MRK) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Merck & Co., Inc. (MRK) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $365 billion, the company is classified as a mega-cap stock, typically characterized by high stability and strong institutional backing.

Financial Performance Analysis

Our comprehensive financial analysis covers Merck & Co., Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Merck & Co., Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Merck & Co., Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Merck & Co., Inc.

Sign Up Free
Corporate Identity

Merck & Co., Inc. (Stock Symbol: MRK) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the NYSE exchange.

Leadership & Workforce

Detailed information about Merck & Co., Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Merck & Co., Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Merck & Co., Inc....

Unlock Full Company Profile

Get complete details about Merck & Co., Inc.

Sign Up Free
Revenue & Growth Analysis

Merck & Co., Inc. generates annual revenues of $67 billion , demonstrating substantial market presence and operational scale.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Merck & Co., Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Merck & Co., Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Merck & Co., Inc....

Unlock Financial Analysis

Get complete financial metrics for Merck & Co., Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Merck & Co., Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Merck & Co., Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mega-cap market leader, the company commands significant market influence, enjoying substantial competitive moats including brand recognition, scale economies, and extensive distribution networks. Mega-cap status typically brings advantages in capital access, talent acquisition, and partnership opportunities, while also attracting the highest levels of institutional investor and analyst coverage.

Industry Competitive Landscape

Merck & Co., Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company demonstrates exceptional operational efficiency through free cash flow generation of $16 billion annually , with year-over-year cash flow growth of 7.7%. This substantial cash generation capability provides significant strategic flexibility for acquisitions, share repurchases, dividend growth, or debt reduction—all while maintaining operational investments necessary to defend market position.

Margin & Pricing Power Analysis

The company maintains a 73.0% gross margin which reflects strong pricing power and/or low direct production costs relative to revenue. Gross margins are only comparable within an industry, so read this level against the company's peers rather than the market as a whole.

Asset Utilization Efficiency

Asset turnover ratio of 0.51x indicates moderate asset turnover. Lower turnover is expected where the business model requires significant infrastructure, so the ratio should be read against the company's own industry.

Financial Strength & Leverage

Current ratio of 1.32 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.

Merck & Co., Inc. (MRK) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Merck & Co., Inc. stock analysis.

Deep dive into Merck & Co., Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Merck & Co., Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Merck & Co., Inc.: With a P/E ratio of 115.14, the market highly values future growth prospects.

P/E Ratio 115.14x
P/B Ratio 8.71x
Market Cap $365.34B
Dividend Yield 2.27%
EPS $1.25
Book Value/Share $17.00
Revenue/Share $26.98
FCF/Share $6.51
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Merck & Co., Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Merck & Co., Inc.: An ROE of 7.6% indicates room for improvement in shareholder value creation.

ROE 7.6%
ROA 2.4%
Gross Margin 73.0%
Net Margin 4.8%
EBT Margin 8.9%
Tax Rate 46.7%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Merck & Co., Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Merck & Co., Inc.: A current ratio of 1.32 shows adequate liquidity.

Current Ratio 1.32x
Quick Ratio 1.10x
D/E Ratio 2.09x
Financial Leverage 3.10x
Working Capital $8.95B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Merck & Co., Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Merck & Co., Inc.: Free cash flow of $16063M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $19.97B
Free Cash Flow $16.06B
Capital Spending -$3.90B
OCF Growth YoY 7.7%
FCF Growth YoY 9.1%
FCF/Sales 24.1%
CapEx/Sales 5.9%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Merck & Co., Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Merck & Co., Inc.: An asset turnover of 0.51x suggests room for improvement in asset utilization.

Asset Turnover 0.51x
Receivables Turnover 5.3x
Inventory Turnover 2.9x
Fixed Assets Turnover 2.6x
Days Sales Outstanding 69 days
Days Inventory 126 days
Payables Period 78 days
Cash Conversion Cycle 117 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Merck & Co., Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Merck & Co., Inc.: With annual revenue of $66569M, Merck & Co., Inc. operates at significant scale.

Income Statement
Total Revenue $66.57B
Net Income $3.17B
R&D Expense $30.45B
SG&A Expense $11.14B
Cost of Goods Sold $18.00B
Balance Sheet Highlights (USD millions)
Total Current Assets $36.68B (28.3% of assets)
Cash & Short-term Investments $6.85B (5.3% of assets)
Accounts Receivable $12.56B (9.7% of assets)
Inventory $6.21B (4.8% of assets)
Total Liabilities $87.82B (67.7% of assets)
Short-term Debt $23.90B (18.4% of assets)
Dividend & Shareholder Information
Dividends Per Share $3.36
Payout Ratio 268.8%
Shares Outstanding 2467M

Latest Merck & Co., Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Merck & Co., Inc. (MRK) stock price and investment outlook.

📰 Loading...

Where MRK sits on the market map

Explore the map →

Merck & Co., Inc. Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Merck & Co., Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
MRK ██% $365.34B 115.1x 8.7x
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
DNTH ██% $5.07B x 4.3x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Merck & Co., Inc. Stock Forecast

How accurate are Merck & Co., Inc. stock predictions?

A per-ticker accuracy statistic for MRK is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Merck & Co., Inc. stock price forecasts?

Our analysis considers Merck & Co., Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Merck & Co., Inc. a good investment in 2026?

Based on our AI analysis, Merck & Co., Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Merck & Co., Inc. forecasts updated?

Merck & Co., Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Merck & Co., Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...